CellBion Co., Ltd. (KOSDAQ:308430)

South Korea flag South Korea · Delayed Price · Currency is KRW
25,500
-950 (-3.59%)
At close: May 20, 2026
Market Cap339.39B +42.0%
Revenue (ttm)1.95B -15.1%
Net Income-7.57B
EPS-591.00
Shares Out12.83M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume55,503
Average Volume109,830
Open26,300
Previous Close26,450
Day's Range24,400 - 26,300
52-Week Range15,700 - 42,200
Betan/a
RSI30.44
Earnings DateApr 13, 2026

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos... [Read more]

Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 308430
Full Company Profile

Financial Performance

In 2025, CellBion's revenue was 1.95 billion, a decrease of -15.05% compared to the previous year's 2.29 billion. Losses were -7.57 billion, 4.23% more than in 2024.

Financial Statements